Axaron Bioscience launches iGentifier - Unique transcription analysis technology identifies the genes that matter

Heidelberg, Germany
April 7, 2003

Axaron Bioscience AG today announced the launch of iGentifier, a novel transcription profiling technology for the agricultural, food, feed, and pharmaceutical industry. This expert technology enables customers to identify genes and biochemical pathways - central to, for example, crop and fungal productivity, pathogenesis and the response to stress factors.

Compared to conventional technologies, iGentifier offers key advantages in terms of robustness, sensitivity and reliability. Combining the advantages of fragment display with tag sequencing methods, iGentifier can detect even the most subtle changes in gene expression. This technology ensures time- and cost-effective transcription analysis that exceeds the limits of microarrays.

Customers benefit from high quality of data regardless of species, sample numbers, or tissue of interest, thereby achieving their goals earlier and seeing a faster return on investment. Axaron’s novel iGentifier technology can be customized to fit seamlessly into customers’ existing genomic platform or as a complete service solution. BASF AG is Axaron’s first customer to use the iGentifier service as part of its crop protection program.

Axaron’s CEO, Dr Alfred Bach comments, "iGentifier is the latest addition to Axaron’s cutting-edge functional genomics and proteomics platform. Based on more than six years experience with customers, we developed iGentifier to combine the advantages of all currently available open transcription profiling technologies. We are convinced that this novel technology will set new standards in transcription profiling in the Life Sciences industry."

Axaron Bioscience is a biotechnology company, which is focused on becoming a leader in developing innovative CNS medicines. The company is in a strong position to achieve this goal based on its unique integrated functional genomics and proteomics technology platform and its world-leading network of collaborating experts in the CNS field. Axaron has already generated an exciting pipeline of drug candidates for the treatment of stroke due to enter Phase II clinical trials later in 2003. Axaron is located in Heidelberg, Germany one of the world’s leading clusters for CNS research. Axaron was founded in 1997 as BASF-LYNX, a joint venture between the German BASF AG and the US biotechnology company Lynx.

News release
5660

OTHER RELEASES FROM THIS SOURCE

Copyright © 2003 SeedQuest - All rights reserved